Business Context and Reporting Period
Clover Health Investments, Corp. filed a Current Report on Form 8-K relating to a board appointment. The earliest reported event occurred on March 25, 2021; the report was signed March 31, 2021. The filing does not report financial results for a specific operating period.
Corporate Governance and Compensation
- The Board increased its size from five to six directors.
- William G. Robinson, Jr., President of Broadgate Human Capital, LLC, was appointed as a Class I director and Chair of the Talent and Compensation Committee.
- Mr. Robinson will receive standard non-employee director compensation, including a pro rata portion of the $70,000 annual cash retainer.
- He will receive a restricted stock unit award under the 2020 Equity Incentive Plan covering Class A common stock with an RSU value of $400,000, pursuant to the Director Compensation Policy.
- Mr. Robinson entered into the company’s standard director indemnification agreement, including provisions for indemnification and advancement of expenses.
Financial Metrics, Liquidity, and Debt
The filing text does not provide revenue, profit, cash flow, margins, debt, liquidity, guidance, or other operating financial metrics.
Material Changes, Outlook, and Risks
The material change disclosed is the addition of a sixth director and the appointment of Mr. Robinson as Chair of the Talent and Compensation Committee. The filing does not provide management guidance, business outlook, new risks, contingencies, or unusual operating items.
The filing states that Mr. Robinson has no family relationships with the company’s directors or executive officers and no direct or indirect material interest in a transaction requiring disclosure under Item 404(a) of Regulation S-K. It also states that there were no arrangements or understandings with other persons regarding his selection.
Investor Verification Items
- Verify the effective date and terms of Mr. Robinson’s director appointment.
- Review the $400,000 RSU award terms, vesting conditions, and potential dilution.
- Confirm the pro rata application of the $70,000 annual director retainer.
- Review the company’s Director Compensation Policy and standard indemnification agreement.
- Assess any subsequent filings for changes to board composition, committee responsibilities, or director compensation.